| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Satellos Bioscience Inc.$9.79
+0.35 (+3.71%)
D 30Pipeline Score Overvalued Pharma · Clinical
Market Cap
140.61 M
EPS
-1.80
P/E Ratio
-
Value Trade
455.05 K
-5.86 %
Week
-12.34 %
1 Month
-40.11 %
3 Month
-90.99 %
6 Month
-99.84 %
5 Year
-99.97 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
165.89 K
52 Week Range
5.50 - 144
% held by Insiders
29.05 %
% held by Institutions
29.31 %
Enterprise Value
70.47 M
Total Shares
20.83 M
Short %
0.47 %
Float Shares
17.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Satellos Bioscience Inc.
40Total events
1Upcoming
3Tier-1 (high impact)
2025 – 2026Coverage
Upcoming catalysts 1
Event history 39
Jul 8, 2026
◆Poster PresentationSAT-3247Presentation
Poster: LT-001 6-month follow-up data from SAT-3247-CL-101 completers
Duchenne muscular dystrophysource ↗
Jul 8, 2026
◆Oral PresentationSAT-3247Presentation
Conference call and webcast to review TRAILHEAD data
Duchenne muscular dystrophysource ↗
Jul 8, 2026
▲Full ResultsSAT-3247Clinical Data
Six-month interim TRAILHEAD data showing reduced muscle fat fraction, increased effort, stable strength, lower CK, favorable safety
Duchenne muscular dystrophysource ↗
Q3 2026
◆Additional DataSAT-3247Clinical Data
Additional data from BASECAMP and TRAILHEAD studies expected in 2H 2026
Duchenne Muscular Dystrophysource ↗
Q3 2026
◆Enrollment CompleteSAT-3247Trial
Enrollment completion in BASECAMP expected in Q3 2026
Duchenne muscular dystrophysource ↗
Q3 2026
◆Trial InitiationSAT-3247Trial
Initiation of US clinical trial sites for TRAILHEAD expected in Q3 2026
Duchenne muscular dystrophysource ↗
Jun 29, 2026
▲Fast Track DesignationSAT-3247Designation
FDA Fast Track Designation for SAT-3247
Duchenne Muscular Dystrophysource ↗
Jun 29, 2026
▲Orphan Drug DesignationSAT-3247Designation
FDA Orphan Drug designation for SAT-3247 in DMD
Duchenne muscular dystrophysource ↗
Jun 29, 2026
▲Rare Pediatric DiseaseSAT-3247Designation
FDA Rare Pediatric Disease designation for SAT-3247 in DMD
Duchenne muscular dystrophysource ↗
May 15, 2026
▲Trial InitiationSAT-3247Trial
TRAILHEAD study initiated in the U.S. in adults aged 16-25 years
Duchenne muscular dystrophysource ↗
Apr 21, 2026
◆Oral PresentationPresentation
Satellos presentation at Bloom Burton & Co. Healthcare Investor Conference
Drug Pipeline Intelligence
D30
Pipeline Score $35M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.3x
rNPV / MCap Top 35%
Micro Cap (rank 593 of 911)
Percentile RankSatellos Bioscience Inc. faces pipeline headwinds (30/100), with $438M risk-adjusted pipeline value, led by SAT-3247 in Duchenne Muscular Dystrophy (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAT-3247 Small molecule | Duchenne Muscular Dystrophy | Phase 2 | NCT06565208 | 46% | $438M | COMPLETED | 128 | - | - | Apr 28, 2025 | MODERATE_RISK | May 15, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SAT-3247 Fast TrackOrphanRare Pediatric | Duchenne muscular dystrophy | — | 2026-07-08 | muscle fat fraction improvement: 3.7%; baseline fat fraction: 49.7%; month 6 fat fraction: 46.0%; te99c baseline: 16.1 joules/kg; te99c month 6: 21.6 joules/kg; te99c improvement: approximately 34%; ck decline: 38% Read More | Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 Read More | |
SAT-3247 Fast TrackOrphanRare Pediatric | Duchenne muscular dystrophy | — | 2026-07-08 | muscle fat fraction improvement: 3.7%; baseline fat fraction: 49.7%; month 6 fat fraction: 46.0%; te99c baseline: 16.1 joules/kg; te99c month 6: 21.6 joules/kg; te99c improvement: approximately 34%; ck decline: 38% Read More | Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 Read More | |
SAT-3247 Fast TrackOrphanRare Pediatric | Duchenne muscular dystrophy | — | 2026-07-08 | muscle fat fraction improvement: 3.7%; baseline fat fraction: 49.7%; month 6 fat fraction: 46.0%; te99c baseline: 16.1 joules/kg; te99c month 6: 21.6 joules/kg; te99c improvement: approximately 34%; ck decline: 38% Read More | Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MSLE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MSLE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MSLE▲ +9.4%on this news
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Bioscience Inc. has reported promising six-month interim data from its TRAILHEAD study of SAT-3247, an investigational drug for adults with Duchenne muscular dystrophy (DMD). The study showed a reduction in muscle fat fraction, increased effort in upper limbs, and stable strength among participants. Additionally, the drug demonstrated a favorable safety profile, with no serious adverse events reported. These findings support the continued clinical evaluation of SAT-3247.
Read more →MSLE▲ +11.4%on this news
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos Bioscience has received FDA Fast Track designation for SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD). This designation, along with Orphan Drug and Rare Pediatric Disease designations, underscores the potential of SAT-3247 in addressing unmet medical needs. The drug is currently being evaluated in ongoing Phase 2 clinical trials, with results expected in the second half of 2026.
Read more →MSLE▲ +19.4%on this news· ran to +38% by day 3shared move
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Inc. will present updates on its SAT-3247 clinical program at the ICNMD 2026 in Florence, Italy. The presentations will include six-month follow-up data from the Phase 1b SAT-3247-CL-101 trial and insights from the ongoing Phase 2 TRAILHEAD trial. SAT-3247 is being developed as a treatment for degenerative muscle diseases, particularly Duchenne muscular dystrophy.
Read more →MSLESatellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, where all management nominees were elected as directors. Shareholder participation reached 55.3%, and the re-appointment of PricewaterhouseCoopers LLP as auditors was approved. The meeting highlighted the company's ongoing commitment to advancing its clinical-stage therapies for degenerative muscle diseases.
Read more →MSLE▲ +5.2%on this news
NOTICE OF MEETING AND MANAGEMENT INFORMATION CIRCULAR RELATING TO THE
Satellos Bioscience Inc. has announced its Annual General Meeting (AGM) set for June 17, 2026, to be held virtually. Shareholders will have the opportunity to receive audited financial statements and vote on board elections. The meeting aims to ensure shareholders can participate remotely, but non-registered attendees will only listen in without the ability to vote. Proxies must be properly registered to ensure voting rights are upheld, following specific instructions outlined in the Management Information Circular.
Read more →MSLESatellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience Inc. reported its financial results for Q1 2026, highlighting significant progress in its clinical trials for SAT-3247, a treatment for Duchenne muscular dystrophy (DMD). The company raised $57 million, providing sufficient funding through 2027. The BASECAMP study is actively enrolling participants, while the TRAILHEAD study has commenced in the U.S. for adults aged 16-25. However, the net loss for the quarter increased compared to the previous year.
Read more →MSLESatellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Bioscience Inc. will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026. CEO Frank Gleeson will lead the presentation and participate in one-on-one meetings. The conference will highlight Satellos's innovative therapy SAT-3247, aimed at treating degenerative muscle diseases.
Read more →MSLE▼ -10.7%on this news
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos Bioscience Inc. reported its 2025 financial results, highlighting key advancements in its clinical programs, including the initiation of the BASECAMP Phase 2 trial for SAT-3247 in Duchenne muscular dystrophy (DMD). The company also presented promising interim data from the TRAILHEAD trial, showing maintained grip strength improvements. Despite an increase in net loss, Satellos secured $57.2 million in equity financing, extending its cash runway through 2027.
Read more →MSLESatellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, Florida. The presentations will include data from a completed Phase 1a/b study of SAT-3247, a drug aimed at treating Duchenne muscular dystrophy, along with new preclinical data. The conference is scheduled for March 8-11, 2026.
Read more →MSLESatellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience Inc. will host a virtual KOL event on February 24, 2026, featuring Dr. Kevin M. Flanigan. The event will discuss the treatment landscape for Duchenne muscular dystrophy (DMD) and provide insights on SAT-3247, an oral therapy aimed at muscle repair. The session will cover results from previous clinical trials and ongoing studies.
Read more →MSLESatellos to Participate in Upcoming Investor Conferences
Satellos Bioscience Inc. announced its participation in several upcoming investor conferences, including the Oppenheimer Healthcare Conference and the TD Cowen Healthcare Conference. The company's leadership will present and hold one-on-one meetings with investors. Satellos is also advancing its drug candidate SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD) through ongoing Phase 2 clinical studies.
Read more →MSLESatellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247's safe
Satellos Bioscience Inc. has announced the dosing of the first participant in its Phase 2 pediatric study, BASECAMP, evaluating the efficacy of SAT-3247 for Duchenne muscular dystrophy. This randomized, double-blind, placebo-controlled trial includes 51 children aged 7 to 9 years and focuses on safety, tolerability, and muscle force impact. The study is considered a potential pivotal trial that could enhance future treatment options for children with Duchenne, as existing therapies are limited. SAT-3247 is a small molecule drug designed to promote muscle regeneration, addressing a significant unmet need in this patient population.
Read more →MSLESatellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Satellos Bioscience Inc. will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, scheduled for February 12, 2026. The event will feature a fireside chat with the company's management, available via live webcast. Additionally, Satellos leadership will hold one-on-one meetings with investors during the conference.
Read more →MSLESatellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
Satellos Bioscience Inc. has completed a public offering, raising approximately US$57.2 million. The offering included the sale of over 5 million common shares and pre-funded warrants. The funds will primarily be used for research and development, particularly advancing the clinical trials of SAT-3247, a drug aimed at treating degenerative muscle diseases.
Read more →MSLEFORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Satellos Bioscience Inc. (the " Company " or " Satellos ") Royal Bank Plaza, South Tower 200 Bay Street, Suite 2800 Toronto, ON M5J 2J1 2. Date of Mater
Satellos Bioscience Inc. recently announced the pricing of a public offering of 4,455,445 common shares at US$10.10 per share, raising approximately US$57.2 million. Alongside this, the company's common shares began trading on the Nasdaq under the ticker 'MSLE'. The capital raised will primarily support ongoing research and development activities, as well as clinical trials for their product SAT-3247. This significant milestone highlights the company's growth and commitment to advancing its therapies in the biopharmaceutical sector.
Read more →MSLESatellos Bioscience Inc. 4,455,445 Common Shares Pre-Funded Warrants to Purchase up to 495,049 Common Shares
Satellos Bioscience Inc. has announced an agreement with Leerink Partners LLC regarding the sale of 4,455,445 common shares and pre-funded warrants to purchase an additional 495,049 common shares. The offering will be made in the United States and Canada under specific regulatory conditions. The exercise price of the pre-funded warrants is set at CAD$0.00001, and there is an option for underwriters to purchase an additional 742,574 common shares. This initiative aims to raise funds and expand the company's financial position in the market.
Read more →Competitive Position
How MSLE ranks across every disease it competes inCompetitive Position is a premium feature
See how MSLE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial